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The number of uncomplicated Escherichia coli (E.coli) induced urinary tract infections (UTIs) per year is 6-8 million in the United States and 130-175 million globally. Anti-microbial resistance has increasingly developed among E. coli strains causing UTIs (Russo and Johnson, 2003) , making understanding of host-defense during UTIs of primary importance. In rodent models of UTIs in which E coli lipopolysaccharide (LPS) is intravesically instilled or intraperitoneally injected (Olsson et al., 1998 , Saban et al., 2001 , Wheeler et al., 2001 ) induction of cyclooxygenase-2, cytokines and inducible nitric oxide synthase (iNOS) along with urothelial exfoliation occur within 4 -24 h. Induction of inflammation by LPS or E.coli in bladder uroepithelial cells involves the Toll-like receptors and CD14 (Schilling et al., 2003) . These activate signaling pathways including nuclear factor-κB and p38 mitogen activated protein kinase with subsequent production of interleukin 6. We have identified another signaling pathway in mouse bladder, the phosphorylation of Akt/protein kinase B (Akt) by phosphatidyl inositol 3-kinase (PI-3-Kinase) which is up-regulated within 30 min of LPS treatment (Tamarkin et al., 2003) . In addition to its role in regulating cell survival and growth signals, phosphorylation of Akt, a serine/threonine kinase, can directly phosphorylate bovine endothelial NOS (eNOS) at serine 1179 and increase NOS activity several fold in endothelial cells (Fulton et al., 1999 , Cirino et al., 2003 . Chronic over-expression of eNOS reduces LPS induced hypotension, lung injury, and death, indicating a protective role for eNOS in septic shock. The co-localization of Akt and eNOS in bladder urothelium, and the rapid phosphorylation of Akt in the bladder after (Tamarkin et al., 2003) may indicate a role for eNOS phosphorylation in the early inflammatory response to LPS.
Three isoforms of NOS have been described in the urinary tract; neuronal NOS, iNOS, and eNOS. NO production by the constitutive, Ca ++ -dependent nNOS causes non-adrenergic, non-cholinergic relaxation in urethral smooth muscle (Dokita et al., 1991) . NO production is dramatically increased by iNOS in bladder inflammation and infection (Wheeler et al., 1997 , Olsson et al., 1998 , Poljakovic et al., 2001 . eNOS is the particulate, Ca ++ -dependent isoform of NOS, which traditionally is considered a constitutive enzyme. There is a high degree of inter-and intra-cell specificity of eNOS expression. eNOS is expressed primarily in the caveolae of epithelial and endothelial cells (Shaul 2002) . eNOS has been localized in mouse bladder and ureteral urothelium (Burnett 1997) , and in mucosal umbrella cells, and in submucosal capillaries of normal adult human urothelium (Shochina et al., 2001) , however, its role in urinary tract function is not well described. Recently, an appreciation has grown for the ability of post-translational modifications to regulate eNOS activity. Factors including shear stress, autocorticoids or growth factors has been hypothesized to induce eNOS or to shift it to a more active state. Dynamic subcellular targeting, protein-protein interactions, and phosphorylation of eNOS through the PI-3-Kinase-Akt pathway modulate NO production by eNOS (Cirino et al., 2003) .
Since upregulation of iNOS requires transcription and translation, phosphorylation of eNOS by Akt provides an attractive mechanism for rapid increases in NO production in LPS treated mice. Mice were treated with an intraperitoneal (IP) injection of LPS. LPS increased levels of urinary cyclic GMP, the downstream product (Olsson et al., 1997) within one hour of LPS injection. We then localized both Akt and eNOS in bladder urothelium. eNOS and phospho-eNOS but not iNOS proteins in the bladder were upregulated within one hour after LPS injection. Because iNOS is the Ca ++ -calmodulin independent isoform of NOS while the constitutive isoforms nNOS and eNOS are Ca ++ -calmodulin dependent, NOS activity was monitored in the presence and absence of EGTA. Only constitutive NOS activity was elevated one hour after LPS treatment. Wortmannin, a PI-3-Kinase inhibitor, reduces Akt phosphorylation in the bladder (Tamarkin et al., 2003) . Wortmannin treatment of LPS treated mice, reduced eNOS phosphorylation. Thus we determined that eNOS is responsible for early increases in NO production in bladder inflammation.
This article has not been copyedited and formatted. The final version may differ from this version. Each experiment was replicated at least 4 times, for a total of at least 8 bladders/experimental condition. LPS was prepared by trichloracetic acid extraction from E. coli, serotype 0127:B8 (Sigma, St. Louis MO). Thirty min to 2 h after injection the animals were sacrificed, and their bladders and hearts removed and placed in ice cold PBS containing phosphatase inhibitors (5 mM sodium fluoride, 1 mM sodium pyrophosphate, 1 mM sodium vanadate). In a second set of experiments, mice were intraperitoneally injected with wortmannin (1.4 mg/kg) in pyrogen free water containing 2% methanol (vehicle) or with vehicle alone (4-6 mice /group). Four h after the initial treatment, all mice were injected with IP LPS (2-3-mice/ group). After one h, the mice were sacrificed and their bladders and hearts processed as above. Prior to any injection and prior to sacrifice, urines were collected from mice by gentle manipulation of the abdomen. (Smith et al., 1996 , Olsson et al., 1998 .
Myeloperoxidase activity was measured in urine or in myeloperoxidase standards (2.5 -12.5 mU/ml) with freshly prepared 1 mM O-dianisidine HCl in 100 mM KH 2 PO 4 (pH 6) plus 0.005% H 2 0 2 . After 10 min, absorbance was read at 450 nm using a Dynatech microplate reader (Chantilly, VA).
Immunoblot analysis. For partial purification of NOS prior to immunoblot analysis, we used the method of Liu and Sessa (1994) . Mouse bladders and hearts were phenylmethylsulfonyl fluoride, protease inhibitor cocktail and phosphatase inhibitors, pH 7.5). Bladders were homogenized (10 s, at 70% power, three times, and 20 s at 50% power) using a Polytron (Brinkmann Instruments, Westbury, NY). Tissue homogenates were incubated on ice (10 min) and centrifuged (10,000 x g, 10 min, 4 0 C). The particulate fraction was re-homogenized (0.5 ml RIPA buffer) and both supernatant and re-homogenized particulate fractions were incubated on ice (10 min) followed by centrifugation (50,000 x g, 20 min). Supernatants were combined and applied to a 0.5 ml column of AG 50W-X8, Na + form (Bio-Rad, Hercules, CA) to remove endogenous Larginine.
NOS activity was then measured in these solubilized preparations as the formation of [ µM FAD, and protease inhibitor cocktail (Olsson et al., 1998) . Activity was measured in the presence of 0.2 U calmodulin-1 mM CaCl 2 . Activity was inhibited with either 2mM
Nω-nitro-L-arginine methyl ester (L-NAME) in order to measure total NOS activity, or with 5 mM EGTA in order to measure constitutive NOS activity. 
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RESULTS
Hematoxylin staining and immunohistochemical localization of Akt and eNOS.
One h LPS treatment did not increase inflammatory cell numbers compared to control bladders. Akt (data not shown), phosphorylated-Akt and eNOS were co-localized in bladder urothelium by IHC (fig 1) .
Effect of LPS treatment on urinary cyclic GMP and myeloperoxidase levels.
Urinary cyclic GMP levels are increased 75% in mice treated with LPS for one h compared to control mice. Wortmannin decreased urinary cyclic GMP levels in control and LPS treated mice (60 min) (fig 2) . Urinary myeloperoxidase levels did not change in these groups of LPS or wortmannin treated mice compared to untreated mice. Urinary levels of cyclic GMP remained elevated in mice treated for 4-18 h with LPS.
Western blot analysis of eNOS, phosphorylated-eNOS and iNOS. One h after LPS
treatment, eNOS and phosphorylated eNOS protein were increased 94% and 151% (n=4), respectively, over control bladder values (fig 3, 4) . The phosphorylation of eNOS in the heart after one h treatment with LPS was increased by 81%+45% compared to controls (fig 4) . iNOS was not detected (not shown) in the one h LPS treated mice. 
Treatment with wortmannin four h prior to a one h LPS treatment reduced
Increases in NOS activity after LPS treatment. LPS treatment of mouse bladders increased Ca
++ -dependent NOS activity (a measure of combined eNOS and nNOS activity) from 9.8 ± 1.9 pmol citrulline/min/mg protein to 18.6 pmol citrulline/min/mg protein (n=5 experiments) within one h. Thus, LPS induced a 90% increase in constitutive, Ca ++ -dependent activity one h after LPS treatment. Ca ++ -dependent NOS activity, in either control or LPS treated mouse bladders, was not significantly different from total NOS activity ( fig. 6 ). LPS did not increase Ca ++ -independent activity (a measure of iNOS) and this activity represented only 5.6% of total NOS activity one h
after LPS treatment (n=5 experiments).
This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
The goal of this study is to show that phosphorylation of eNOS, a posttranslational modification, can rapidly increase NO production in the bladder. One h after treatment with IP LPS, urinary cyclic GMP, eNOS protein and phosphorylation, and constitutive bladder NOS activity are all increased. This indicates that eNOS phosphorylation along with increases in eNOS protein may be involved in the early response to bladder inflammation. Increases in NO production during urinary tract infections (Wheeler et al., 1997) , Bacille Calmette-Guerin treatment of bladder cancer (Jansson et al., 1998) , and transplant rejection (Smith et al., 2000) previously have been linked to iNOS activation. In mouse and rat models where inflammation was induced with LPS, upregulation of iNOS in the bladder occurs after 4 h (Olsson et al., 1998 , Saban et al., 2001 , Poljakovic et al., 2001 . After one h of LPS treatment, there is no increase in the number of inflammatory cells stained with hematoxylin or in urinary myeloperoxidase, a specific marker for neutrophils, as compared to controls. The static number of inflammatory cells after one h of LPS treatment indicates that changes in eNOS occur in urothelial cells and are not due to an influx of inflammatory cells that occurs four h after LPS treatment in a rat UTI model (Olsson et al., 1998) .
Increases in urinary cyclic GMP reflect an increase in NOS, which may occur in the bladder as well as in other tissues. In the rat model of bladder inflammation, intravesical instillation of LPS increases urinary nitrate/nitrite levels to the same level as intraperitoneal injection of LPS (Wheeler et al., 2001) . Intravesical instillation of LPS does not increase NOS activity or iNOS mRNA in either the heart or the kidney (Olsson et al., 1998) . Therefore, increases in NOS activity may be due in a large part to In humans (Shochina et al., 2001 ) and in mice (Burnett et al., 1997) , eNOS is localized in bladder urothelium. We have recently shown that Akt, a signaling protein activated by PI-3-kinase, can directly phosphorylate eNOS and is also localized in mouse urothelium. Akt phosphorylation in mouse bladder is evident within 30 min of treatment with LPS and increases for 2 h. Wortmannin, a specific inhibitor of PI-3-kinase, blocks LPS induced Akt phosphorylation in mouse bladder (Tamarkin et al., 2003) and also blocks LPS induced eNOS phosphorylation. The reduction in eNOS phosphorylation in the bladder and urinary cyclic GMP following wortmannin treatment indicates that the PI-3-kinase/Akt pathway is involved in the early response to LPS induced-inflammation.
Increases in NO in response to shear stress, estradiol, insulin like growth factor, and VEGF have been linked to eNOS phosphorylation by Akt in endothelial cells (Shaul 2002) . In a whole animal model of portal hypertension, eNOS phosphorylation and NO production are up-regulated in the superior mesenteric artery (Iwakiri et al., 2002) . Both electrical stimulation of the cavernous nerve and direct intracavernosal injection of papaverine, a vasorelaxant drug, cause rapid (after 15 s) increases in the phosphorylation of Akt and eNOS. This phosphorylation is reduced by wortmannin and by LY294002, another inhibitor of PI3-kinase. Both wortmannin and LY294002 reduce erections. While NO production is rapidly increased by stimulation of nNOS, eNOS may be responsible for sustained NO production and maximal erection (Hurt et al., 2002) . 
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In addition to LPS induced increases in eNOS phosphorylation, we also noted increases in eNOS protein in bladder one h after IP injection of LPS. This increase in eNOS protein was not changed by treatment with wortmannin. Several lines of evidence, in addition to data presented in this manuscript, point to the upregulation of eNOS as an early event in inflammatory processes of the bladder urothelium as well as of the gastric mucosa. In rats, eNOS and iNOS mRNA and protein along with eNOS immunoreactivity in the urothelium are increased two h after BCG transurethral injection (Oh et al., 2001) . In urinary bladder tumor biopsy specimens, Ca ++ dependent NOS activity was several fold higher in BCG-treated bladder, compared to normal bladder wall and bladder tumor. eNOS immunoreactivity is detected in urothelial cells and in BCG treated bladder mucosa (Jansson et al., 1998) . In rat gastric mucosa increases in both eNOS mRNA and iNOS mRNA are noted one h after IP injection of LPS. At three and five h after IP LPS, iNOS but not eNOS remains elevated. Evaluation of gastric luminal nitrate and nitrite levels, another measure of NO, is also increased after one h of LPS treatment. Unlike the bladder, however, upregulation of NO may be due to increases in iNOS since Ca ++ -independent, but not Ca ++ -dependent NOS activity, is elevated in gastric mucosa after one h of LPS treatment (Helmer et al., 2002) . In the mouse bladder, after one h of treatment with LPS, we found an increase in Ca ++ -dependent but not Ca ++ -independent NOS activity. The mechanism for upregulation of eNOS protein in urothelium has not been elucidated. In endothelial cells, increases in eNOS protein by a variety of stimuli are associated with increases in protein synthesis, mRNA levels (Zembowicz et al., 1995) or mRNA half-life (Laufs and Liao, 1998) . In endothelial cells, however, the upregulation of eNOS occurs after three h or more. 
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While eNOS has been localized to the urothelium, its function in the bladder has not been delineated. The role of NO produced by eNOS in septic shock is seen as protective compared to the deleterious effect of NO produced by iNOS. LPS injection in mice over-expressing eNOS causes significantly less mortality than LPS injection in mice that do not over-express eNOS. When treated with LPS, mice that chronically over-express eNOS in their endothelium were resistant to LPS-induced hypotension, lung injury and death (Yamashita et al., 2000) . In the urinary tract, induction of eNOS protein and phosphorylation may play a role in the pathophysiology of inflammatory processes in the bladder. PI-3-kinase is involved not only in the bladder response to LPS, but also in bacterial adherence and invasion induced by type 1 pilus adhesin (FimH) encoded by uropathogenic E. coli (Martinez and Hultgren 2002) . Since PI-3 Kinase-Akt activation induces phosphorylation of eNOS, bacterial adherence and invasion may also involve eNOS. Both eNOS and iNOS mRNA, are detected in the urine from subjects with UTIs (Wheeler et al., 1997) . Increases in NO production during BCG treatment of subjects with bladder cancer may be linked to eNOS as well as iNOS (Jansson et al., 1998) . Urinary NOS activity and cyclic GMP levels are decreased in subjects with interstitial cystitis compared to control subjects (Smith et al., 1996 , Erickson et al., 2002 perhaps indicating that eNOS is down-regulated in this patient population. Since the NO produced by eNOS is believed to be beneficial, the role of phosphorylation of eNOS by PI-3-kinase in up-regulating NO production during UTIs and during BCG treatment of subjects with bladder cancer, and its role in the downregulation of NOS in interstitial cystitis, should be subjected to further investigation. 
